Blackford first platform to offer both SubtlePET and SubtleMR for enhancement of medical imaging.
Edinburgh, UK & Menlo Park, CA – June 09, 2020 – Blackford announced today that it is the first and only platform provider to offer both SubtlePET™ and SubtleMR™, the first FDA-cleared AI-powered software applications approved for medical imaging enhancement, from Subtle Medical.
SubtleMR is a deep learning-based image enhancement technology that delivers better image quality from accelerated protocols using resolution enhancement and denoising. Unlike conventional processing approaches that can obscure image detail, SubtleMR can improve quality and increase SNR and resolution. It can be used with any scanner and field strength.
SubtlePET has been shown to denoise scans that were conducted in 25% of the original scan duration. The software allows centers to increase throughput by maintaining the superior image quality of site accelerated scan protocols.
Both SubtlePET and SubtleMR are developed from proprietary deep learning algorithms that integrate seamlessly with any PET or MRI scanner and PACS to enhance images during acquisition without any alteration to existing workflows.
“We’re excited to be the first provider to offer both of Subtle’s AI enhancement applications on our Curated Marketplace,” said Ben Panter, CEO, Blackford Analysis. “In addition to helping improve workflow efficiency and patient experience, they are two of several applications now available on the Blackford Platform that can help support hospitals with the predicted increase in post-COVID imaging volume.”
Fully integrated with existing systems, the Blackford Platform simplifies the implementation and management of multiple imaging applications and AI algorithms and reduces load on PACS. New applications can easily be added to the image-processing platform, reducing implementation time, cost, and long-term maintenance.
“It’s a great time to broaden our partnership with Blackford as it allows us to reach hospitals and imaging centers more quickly who can benefit from Subtle products. Given the surge of postponed imaging procedures anticipated to arise over the next few months due to Covid-19, SubtleMR and SubtlePET will allow these centers to process the backlog without compromising image quality,” said Enhao Gong, Founder & CEO, Subtle Medical.
© Blackford Analysis 2020 blackfordanalysis.com
About Subtle Medical
Subtle Medical, Inc. is a healthcare technology company with a suite of deep learning solutions that improve workflow efficiency and patient experience. The company has the first AI software solutions FDA-cleared for medical imaging enhancement, SubtlePET™ and SubtleMR™. It was named in the CB Insights Top AI 100 in 2020. Current clinical partners include UCSF, Hoag Hospital, UCSD, Toronto SickKids, Radnet, DASA, Tiantan Hospital, and Middlesex Hospital, among others. Subtle Medical is based out of Menlo Park, CA. For more information, please visit subtlemedical.com or email email@example.com.
Blackford provides a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. www.blackfordanalysis.com
Greg Kingston – Blackford
T: +44 7841 688 602